Rise in Drug-Resistant Neurological Conditions
An increase in the prevalence of drug-resistant neurological conditions, especially epilepsy, has been observed in South and Central America, and this is expected to play an increasingly influential role in shaping the clinical demand for vagus nerve stimulators. Countries such as Brazil, Argentina, Colombia, and Chile have seen rising levels of epilepsy diagnoses attributed to improvements in both diagnostic services and healthcare infrastructure. While the number of anticonvulsant drugs that are available increases, many people still struggle with epilepsy despite taking these medications, highlighting the need for neuromodulation treatment.
Countries in South and Central America are increasingly building capacity for complex neurological care by establishing tertiary hospitals and epilepsy clinics. In countries such as Brazil, where public hospitals make up the majority of the healthcare infrastructure, the trend toward complex neurological procedures has taken hold, specifically in cities such as São Paulo and Rio de Janeiro. Likewise, Chile and Colombia are expanding their scope of neurodiagnosis and making advances in public and private hospitals, identifying more candidates for vagus nerve stimulators.
In addition to epilepsy, the region is experiencing a rising incidence of neurological complications linked to traumatic brain injuries, infectious diseases affecting the nervous system, and chronic non-communicable conditions. Road traffic accidents in countries such as Peru and Brazil contribute significantly to long-term neurological disability, while metabolic disorders like diabetes are increasing neuropathy cases. These evolving disease patterns are encouraging clinicians to consider non-pharmacological, long-term neuromodulation approaches for managing refractory neurological conditions.
Extending to New Therapeutic Indications
The South and Central America vagus nerve stimulation devices market is gradually expanding beyond epilepsy into a broader range of therapeutic applications. Healthcare providers in Brazil, Mexico (often considered part of broader Latin American market dynamics), and Argentina are increasingly evaluating vagus nerve stimulation for treatment-resistant depression, chronic migraine, and anxiety disorders. Growing awareness of mental health conditions and improving access to psychiatric services are supporting the integration of neuromodulation into multidisciplinary care models.
There is an increasing interest in adopting non-invasive vagus nerve stimulation devices in this region because of the feasibility of using such devices in an outpatient setting and within cost-effective health delivery setups. The use of external stimulators is very suitable in those countries where there is not much availability of neurosurgery facilities, except in big hospitals within urban areas.
Moreover, cooperation between the academic institutions in the region and international firms specializing in medical devices has helped spur the development of clinical trials in the field of vagus nerve stimulation for other applications. The universities and neuroscience facilities in Brazil and Chile have focused on developing the application for stroke recovery, chronic pain treatment, and cognitive impairment. With better training for physicians and the growing amount of clinical evidence, the gradual adoption of vagus nerve stimulation technology can be anticipated in the region.
